Spatially-resolved models of some genomic aberrations in gliomas (e.g. copy number variations in EGFR, PDGFR, etc.)have already been developed, with accuracies ranging from 37.5% to 87.% depending on the gene of interest (Figure 2) (28, 60, 61). This evidence concerns the gene PDGFRB and central nervous system cancer.